Prognostic importance of DNA from human papillomavirus in patients with oral squamous cell carcinoma

• Elizabeth Pérez-Islas ^[1] ; Alejandro García-Carrancá ^[1] ; Enrique Acosta-Gio ^[1] ; Nancy Reynoso-Noverón ^[2] ; Héctor A Maldonado-Martínez ^[3] ; Miriam Guido-Jiménez ^[1] ; Nora Sobrevilla-Moreno ^[4] ; Martín Granados-García ^[5] ; Wendy B Pérez-Báez ^[6] ; Diana Vilar-Compte ^[7]
  1. [1] Universidad Nacional Autónoma de México

     Universidad Nacional Autónoma de México

     México

     
  2. [2] Epidemiology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico
  3. [3] Department of Surgical Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico
  4. [4] Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico
  5. [5] Head and Neck Surgery Department, Instituto Nacional de Cancerología, Mexico City, Mexico
  6. [6] Department of Molecular Biology, Instituto Nacional de Cancerología, Mexico City, Mexico
  7. [7] Hospital Epidemiology, Department of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City, Mexico

  Mostrar afiliaciones +
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 27, Nº. 2 (March), 2022
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Survival of patients with oral squamous cell carcinoma (OSCC) is generally low, with the likelihood of locoregional recurrence or disease progression (LR/DP). Knowledge of prognostic factors for survival is key to achieving an understanding and increased survival. The present study aimed to identify prognostic factors for patients with OSCC, especially the presence of DNA from human papillomavirus (HPV).

    Retrospective cohort study including 119 patients with OSCC treated at the National Cancer Institute in Mexico City (2009-2013). Clinical information was obtained from patient records including LR/DP. Formalin-fixed, paraffin-embedded tissues were obtained and used for detecting DNA from different types of HPV. Potential prognostic factors for Overall Survival (OS) were analyzed using the Cox proportional hazards model.

    After model adjustment, factors associated with longer OS were a pre-treatment platelet count above 400,000/mm3 (HR=0.09, p=0.026) and response to primary treatment (HR=0.26, p=0.001). HPV DNA was present in 23 (19.3%) of the patients and importantly, type 16 found in 19 of them. Although survival of HPV-positive patients was longer, difference was not significant. However, among patients with LR/DP, HPV positivity was significantly associated with increased survival (HR=0.23, p=0.034). Importantly, survival was significantly different for HPV-positive patients with LR/DP > 6 months (HR=0.20, p=0.002), had higher absolute lymphocyte count at start of treatment (HR=0.50, p=0.028) or had local rescue treatment (HR=0.24, p=0.019).

    Although HPV positivity was not associated with a longer OS of OSCC patients, a better prognosis was significantly associated with HPV positivity and recurring or progressing disease, particularly with HPV type 16.